



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2018

Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series

Anzengruber, Florian ; Drach, Mathias ; Maul, Julia-Tatjana ; Kolios, Antonios G ; Meier, Barbara ; Navarini, Alexander A

DOI: <https://doi.org/10.1111/jdv.14808>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-146640>

Journal Article

Accepted Version

Originally published at:

Anzengruber, Florian; Drach, Mathias; Maul, Julia-Tatjana; Kolios, Antonios G; Meier, Barbara; Navarini, Alexander A (2018). Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series. *Journal of the European Academy of Dermatology and Venerology*, 32(7):e274-e276.

DOI: <https://doi.org/10.1111/jdv.14808>

Article type : Letter to Editor

Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.

Running head: HLA-Cw6 status in psoriasis patients under Secukinumab

Florian Anzengruber^{1,3}, Mathias Drach^{1,3}, Julia-Tatjana Maul^{1,3}, Antonios G. Kolios^{1,2,3},
Barbara Meier^{1,3}, Alexander A. Navarini^{1,3}

¹Department of Dermatology, University Hospital Zurich, Zurich, Switzerland

²Department of Immunology, University Hospital Zurich, Zurich, Switzerland

³Faculty of Medicine, University of Zurich, Zurich, Switzerland

Corresponding author:

Prof. Dr. Dr. Alexander Navarini

Department of Dermatology

University Hospital Zurich

Gloriastrasse 31

8091 Zurich

alexander.navarini@usz.ch

Tel.: + 41 44 255 11 11

Fax.: +41 44 255 45 49

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jdv.14808

This article is protected by copyright. All rights reserved.

Key words: human leucocyte antigen, Cw6, genetic variations, HLA-Cw6, secukinumab, psoriasis.

Conflict of interest: F.A. has received honoraria from Novartis and Eli Lilly. A.A.N, M. D., J.T. M., B. M. and A.K have no conflicts of interest related to this work.

To the Editor

Physicians can treat psoriasis patients with several effective treatments, however the response is individual and even the most effective therapies do sometimes not lead to a success of treatment. Currently, possible genetic markers that can predict individual therapy response are investigated.

Up to now 45 genes have been identified to be associated with psoriasis [1]. Of all genes, HLA-C*06, or also known as HLA-Cw6 or PSORS1 displays the strongest association [2]. This allotype is not only a risk factor for psoriasis, but has also been found of use in predicting therapy responses. Previous studies had shown a higher response rate of HLA-Cw6+ patients for TNF-alpha [3], methotrexate [4] and especially ustekinumab [5-7]. Li et al. analysed 523 patients [5]. HLA-Cw6+ patients tended to have a higher response rate to ustekinumab. This difference was however only modest and potentially of limited clinical utility. Most clinical centers including tertiary referral centers do not tend to accumulate hundreds of moderate-to-severe psoriasis patients treated with a single drug. Therefore, it is of interest to investigate whether the screening of HLA-Cw6 is of clinical utility in a day-to-day clinic. If so, we hypothesized, prescreening could possibly enhance patient care and aid clinical treatment decisions.

The patients presented to our clinic between 1 January 2010 and 31 March 2017 were included after signing an informed consent. We retrospectively collected HLA-genotyping data from patients. Genomic DNA was isolated from ethylenediamine tetraacetic acid

(EDTA) tubes with venous blood. The samples were genotyped using a primer-specific polymerase chain reaction (Olerup HLA-C*06-SSP® product number 101.614-12u, Vienna, Austria).

Secukinumab was administered in the standard doses and treatment responses were measured at 3 months by PASI.

18 patients (7 women, 11 men) were included in this retrospective study. On average, the patients were 46.4 ± 9.5 (21-61) years old and the PASI at baseline was 8.2 points. 10 patients were positive for the HLA-Cw6 allele, 8 were negative.

The majority of patients in both groups reached PASI 50 (Table 1), but not PASI 75 or PASI 90. The average PASI improvement was 74.2% (Cw6+) vs. 62.4% (Cw6-), showing no significant difference ($p = 0.397$) between these two groups (Figure 1).

On average, our patients had a lower PASI baseline than in comparable studies. In randomized, clinical trials patients tend to have a higher PASI since patients need to be treatment naïve or have not performed treatment for a certain amount of time. Our real life data includes patients that had previously been treated - even with other biologics - explaining this lower baseline PASI.

Even though we did not find significant differences in our small cohort, a larger trial might indeed show a statistical difference. Using the published data for predicting success of ustekinumab at 16 weeks with HLA-Cw6 [5], a power analysis ($\alpha = 0.05$, power= 90%) shows that overall 216 patients would be needed to confirm such a difference. As most centers treat their patients with a variety of anti-psoriasis drugs, the average amount of patients under secukinumab per clinic will be usually way below this number. In addition, other than for purposes of treatment response prediction, routine HLA-Cw6 testing might not be justified from a health economy perspective. We believe that for a tertiary hospital with less than 20 patients treated with secukinumab, this statistical difference is not actionable and of relevance to patients. Therefore, even though larger studies could in the future demonstrate a statistical tendency for differential treatment responses for secukinumab in certain HLA allotypes, HLA-Cw6 testing might not be warranted at this time.

References

1. Liang, Y., et al., *Psoriasis: a mixed autoimmune and autoinflammatory disease*. *Curr Opin Immunol*, 2017. **49**: p. 1-8.
2. Nair, R.P., et al., *Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C*. *Am J Hum Genet*, 2000. **66**(6): p. 1833-44.
3. Batalla, A., et al., *The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients*. *Pharmacogenet Genomics*, 2015. **25**(6): p. 313-6.
4. Indhumathi, S., et al., *Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis*. *Eur J Clin Pharmacol*, 2017. **73**(8): p. 965-971.
5. Li, K., et al., *HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program*. *J Invest Dermatol*, 2016. **136**(12): p. 2364-2371.
6. Chiu, H.Y., et al., *Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis*. *Br J Dermatol*, 2014. **171**(5): p. 1181-8.
7. Talamonti, M., et al., *HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up*. *J Am Acad Dermatol*, 2016. **74**(2): p. 374-5.

Tables and Figure legends

Table 1.

Patients' characteristics, PASI at baseline and treatment response.

Figure 1.

Treatment response after 12 weeks.

Table 1.

Patients' characteristics, PASI at baseline and treatment response.

	all	Cw6+	Cw6-
Patients (n)	18	10	8
Age	46.4 ± 9.5 (21-61)	46 ± 6.67 (21-61)	47 ± 12.86 (33-53)
Sex			
Male	12	7	5
Female	8	3	5
PASI at baseline	8.2 ± 6.3 (0-26.7)	8.65 ± 4.9 (0-17.8)	7.73 ± 8.4 (0-26.7)
PASI ≤5	5	2	3
PASI 5-10	7	3	4
PASI ≥ 10	6	5	1
Treatment response			
PASI 50	11	6 (10)	5 (8)
PASI 75	10	5 (10)	5 (8)
PASI 90	5	3 (10)	2 (8)
Average PASI improvement	64.96 ± 36.83	74.2% ± 36.1	62.4% ± 39.8

